Paladin Labs Inc. Expands Distribution Agreement with Shire Human Genetic Therapies HGT to Include ELAPRASE(TM) (Idursulfase)

MONTREAL, CANADA--(MARKET WIRE)--Aug 8, 2007 -- Paladin Labs Inc. (Toronto:PLB.TO - News), a leading Canadian specialty pharmaceutical company, today announced that it has expanded its current exclusive Canadian distribution agreement with Shire Human Genetic Therapies, Inc. (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ). Under the new agreement, Paladin will be distributing ELAPRASE(TM) (idursulfase) for Hunter syndrome in addition to REPLAGAL® (agalsidase alfa) for Fabry disease. Health Canada recently granted Shire HGT regulatory approval for ELAPRASE, indicated for enzyme replacement therapy in patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II).